Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 12/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20690493 | 0.87 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3MEN1 | |
| SCHEMBL12326836 | 0.87 | MAPT (0.51) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL3847201 | 0.85 | PARP1 (0.59) | TSHRLMNAPOLBMEN1KMT2A | |
| SCHEMBL16960436 | 0.85 | CHEK1 (0.47) | CASP6TSHRLMNAHCAR3MEN1 | |
| SCHEMBL29886656 | 0.83 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL1265098 | 0.83 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL6867539 | 0.83 | CASP6 (0.55) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL8129652 | 0.83 | ALDH1A1 (0.53) | CASP6TSHRLMNAHCAR3MEN1 | |
| SCHEMBL8129502 | 0.83 | VCAM1 (0.63) | LMNAMEN1KMT2A | |
| SCHEMBL8149078 | 0.83 | CHEK1 (0.55) | CASP6TSHRLMNAHCAR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3385253-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Lantheus Medical Imaging, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-1713512-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-0632036-B1 | Amide derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO CO (JP) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0135901-B1 | HEAT-SENSITIVE REGISTRATION MATERIAL | JUJO PAPER CO., LTD. (JP) | 1988-11-30 | — | — | EP | disclosed |
| US-4591888-A | IMPROVED STABILITY AGAINST CONTAMINATION WITH OILY SUBSTANCES | JUJO PAPER CO., LTD. (JP) | 1986-05-27 | — | — | US | disclosed |
| EP-0135901-A2 | Heat-sensitive registration material | JUJO PAPER CO., LTD. (JP) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CASP6 4638/4885TSHR 2215/4885LMNA 3348/4885 |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | CASP6 4638/4885TSHR 2215/4885LMNA 3348/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CASP6 4638/4885TSHR 2215/4885LMNA 3348/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | CASP6 1116/4885TSHR 2036/4885LMNA 80/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | CASP6 4638/4885TSHR 2215/4885LMNA 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.